Chromosomal aberrations induced by imipramine and desipramine in mouse

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Imipramine (IMI) and desipramine (DES) are two drugs widely used for the treatment of depression as well as for other diseases. In the present study, we determined their capacity to induce chromosomal aberrations in mouse bone marrow cells. Three doses of each compound were tested and their results were compared with the frequency of chromosomal aberrations obtained in a control group as well as with a group treated with cyclophosphamide. Our results showed a significant increase in chromosome damage with the doses tested for each compound: 7, 20, and 60 mg/kg in the case of IMI, and 2, 20, and 60 mg/kg as regards DES. This last drug induced stronger chromosomal damage than IMI. Our results agree with previous studies regarding the induction of micronuclei and sister chromatid exchanges by the drugs in mouse and suggest caution with respect to their use in long-term treatments.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalHuman and Experimental Toxicology
Volume29
Issue number4
DOIs
StatePublished - Apr 2010

Keywords

  • Chromosomes
  • Desipramine
  • Imipramine
  • Mouse

Fingerprint

Dive into the research topics of 'Chromosomal aberrations induced by imipramine and desipramine in mouse'. Together they form a unique fingerprint.

Cite this